Related Experiment Video

Updated: Nov 7, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.4K

Expanding armamentarium in advanced prostate cancer management: are all novel antiandrogens the same?

Emre Yekedüz1, Güngör Utkan1, Ravindran Kanesvaran2

  • 1Department of Medical Oncology, Ankara University School of Medicine, Ankara, Turkey.

Prostate International
|April 29, 2021
PubMed

Insights

New anti-androgen drugs show promise for prostate cancer (PCa) treatment. This review compares new generation anti-androgen (AA) drugs, including their use in castration-sensitive prostate cancer.

Area of Science:

  • Oncology
  • Urology

Background:

  • Prostate cancer (PCa) is a leading cancer in men, driven by the androgen receptor (AR) axis.
  • Androgen deprivation therapy (ADT) is standard, but resistance is common.
  • Newer anti-androgen (AA) drugs offer advanced treatment options.

Purpose of the Study:

  • To review and compare the structure, mechanism of action, and clinical outcomes of novel second-generation anti-androgen drugs.
  • To evaluate the efficacy of these agents in both castration-resistant and castration-sensitive prostate cancer settings.

Main Methods:

  • Comparative review of phase 3 clinical trial data.
  • Analysis of drug structures and mechanisms of action.
  • Synthesis of recent scientific literature on new generation AAs.

Main Results:

  • Newer AAs demonstrate varying efficacy and safety profiles across different patient populations.
  • Emerging data suggests potential benefits of these agents in earlier stages of prostate cancer (castration-sensitive).

Conclusions:

  • Second-generation anti-androgens represent a significant advancement in prostate cancer management.
  • Further research is warranted to optimize treatment strategies and expand the use of these drugs.
Keywords:
Androgen Receptor AntagonistsAndrogen-Resistant Prostatic CancerProstatic Neoplasms

More Related Videos

Serum and Plasma Copy Number Detection Using Real-time PCR09:21

Serum and Plasma Copy Number Detection Using Real-time PCR

Published on: December 15, 2017

11.6K
Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses08:36

Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses

Published on: October 24, 2019

11.4K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K